![logo](/logos/300639.SZ.webp)
Guangdong Hybribio Biotech Co.,Ltd.
SZSE:300639.SZ
8.67 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 1,094.129 | 5,596.971 | 2,673.023 | 1,354.497 | 729.393 | 580.352 | 479.085 | 398.304 | 344.834 | 264.083 | 182.718 | 139.014 |
Cost of Revenue
| 521.746 | 1,714.664 | 865.181 | 360.753 | 141.586 | 95.779 | 78.577 | 57.073 | 41.791 | 36.217 | 32.565 | 31.698 |
Gross Profit
| 572.382 | 3,882.307 | 1,807.842 | 993.743 | 587.807 | 484.573 | 400.508 | 341.231 | 303.043 | 227.866 | 150.152 | 107.317 |
Gross Profit Ratio
| 0.523 | 0.694 | 0.676 | 0.734 | 0.806 | 0.835 | 0.836 | 0.857 | 0.879 | 0.863 | 0.822 | 0.772 |
Reseach & Development Expenses
| 117.511 | 247.281 | 115.294 | 71.622 | 57.447 | 45.95 | 33.559 | 31.873 | 31.51 | 17.705 | 20.377 | 19.019 |
General & Administrative Expenses
| 88.756 | 143.238 | 88.818 | 67.327 | 56.424 | 50.433 | 38.905 | 20.79 | 19.295 | 15.485 | 44.219 | 36.992 |
Selling & Marketing Expenses
| 279.123 | 460.212 | 382.676 | 313.111 | 260.448 | 217.545 | 183.119 | 159.989 | 143.027 | 101.461 | 68.426 | 48.184 |
SG&A
| 446.451 | 603.45 | 471.494 | 380.438 | 316.873 | 267.978 | 222.023 | 180.778 | 162.322 | 116.946 | 112.645 | 85.176 |
Other Expenses
| -11.641 | 256.634 | 114.349 | 66.031 | 63.126 | -0.076 | -0.569 | 4.49 | 3.148 | 0.799 | 0.319 | 1.047 |
Operating Expenses
| 575.603 | 1,107.365 | 701.137 | 518.091 | 437.445 | 367.432 | 295.628 | 257.811 | 228.997 | 154.569 | 114.18 | 86.177 |
Operating Income
| -3.221 | 2,193.17 | 1,073.78 | 468.84 | 156.253 | 126.014 | 110.065 | 80.429 | 71.962 | 72.108 | 33.145 | 21.325 |
Operating Income Ratio
| -0.003 | 0.392 | 0.402 | 0.346 | 0.214 | 0.217 | 0.23 | 0.202 | 0.209 | 0.273 | 0.181 | 0.153 |
Total Other Income Expenses Net
| 40.88 | -65.304 | -16.599 | -4.864 | -1.73 | 8.798 | -0.569 | 4.469 | 2.188 | 0.693 | -0.022 | 1.047 |
Income Before Tax
| 37.659 | 2,127.866 | 1,057.181 | 463.976 | 154.523 | 125.939 | 109.496 | 84.899 | 74.15 | 72.801 | 33.123 | 22.371 |
Income Before Tax Ratio
| 0.034 | 0.38 | 0.396 | 0.343 | 0.212 | 0.217 | 0.229 | 0.213 | 0.215 | 0.276 | 0.181 | 0.161 |
Income Tax Expense
| -31.698 | 326.464 | 172.244 | 69.319 | 17.567 | 19.196 | 17.733 | 10.335 | 9.734 | 9.342 | 3.953 | 2.647 |
Net Income
| 140.472 | 1,725.998 | 852.16 | 362.662 | 147.291 | 114.08 | 93.21 | 76.095 | 65.212 | 63.459 | 29.17 | 19.725 |
Net Income Ratio
| 0.128 | 0.308 | 0.319 | 0.268 | 0.202 | 0.197 | 0.195 | 0.191 | 0.189 | 0.24 | 0.16 | 0.142 |
EPS
| 0.25 | 2.65 | 1.3 | 0.59 | 0.25 | 0.19 | 0.17 | 0.17 | 0.14 | 0.15 | 0.073 | 0.046 |
EPS Diluted
| 0.25 | 2.65 | 1.3 | 0.59 | 0.25 | 0.19 | 0.17 | 0.17 | 0.14 | 0.15 | 0.073 | 0.046 |
EBITDA
| 189.105 | 2,920.835 | 1,201.454 | 529.754 | 200.552 | 161.442 | 140.236 | 111.793 | 90.936 | 86.413 | 38.046 | 22.184 |
EBITDA Ratio
| 0.173 | 0.522 | 0.449 | 0.391 | 0.275 | 0.278 | 0.293 | 0.281 | 0.264 | 0.327 | 0.208 | 0.16 |